Hussein Azzam, MD
Allergy & Immunology · Novi, MINPI 1144688854
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 352 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations.
Across 352 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$1K
- AstraZeneca$914
- GSK$824
- Optinose US, Inc.$533
- Kaleo, Inc.$371
- plus $2K from 21 others
What the payments were for
- Food & beverage$7,19499%
- Education$1091%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 54 | $1,415 |
| Sanofi | 56 | $1,227 |
| AstraZeneca | 48 | $914 |
| GSK | 51 | $824 |
| Optinose US, Inc. | 30 | $533 |
| Kaleo, Inc. | 14 | $371 |
| Genentech USA, Inc. | 18 | $276 |
| Novartis | 12 | $240 |
| Teva Pharmaceuticals USA, Inc. | 11 | $201 |
| Boehringer Ingelheim | 10 | $194 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $128 |
| Sanofi-aventis U.S. LLC | 2 | $92 |
| Aimmune Therapeutics, Inc. | 5 | $92 |
| Octapharma USA, Inc. | 3 | $79 |
| LEO Pharma Inc. | 4 | $73 |
| Organon | 3 | $73 |
| Amgen | 3 | $73 |
| Grifols USA, LLC | 3 | $69 |
| Pfizer | 3 | $64 |
| Hikma Pharmaceuticals USA | 4 | $62 |
| AbbVie | 2 | $41 |
| Merck | 2 | $36 |
| Tersera Therapeutics LLC | 1 | $29 |
| Dermavant Sciences, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $22 |
| Phadia US Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$247
How this compares
$7,303 in reported general payments places this provider in the 75th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 32 | $124,504 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $82,790 |
| Breo ElliptaFluticasone/Vilanterol | 72 | $51,638 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 115 | $23,877 |
| AdbryTralokinumab-Ldrm | 11 | $21,077 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $13,510 |
| DuleraMometasone/Formoterol | 13 | $6,797 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $5,309 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $4,905 |
| Fluticasone Propionate | 172 | $4,817 |
| Wixela InhubFluticasone Propion/Salmeterol | 26 | $4,088 |
| Arnuity ElliptaFluticasone Furoate | 14 | $3,562 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $3,554 |
| Epinephrine | 11 | $3,154 |
| Azelastine Hcl | 73 | $2,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $824 | $137,990161 claims |
| LEO Pharma Inc.Adbry | $73 | $21,07711 claims |
| AstraZenecaSymbicort | $914 | $13,51037 claims |
| MerckDulera | $36 | $6,79713 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $201 | $4,90512 claims |
| Hikma Pharmaceuticals USAEpinephrine | $62 | $3,15411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 119 allergy & immunology providers in Michigan.
Other allergy & immunology in Novi
- Malathi BathijaNovi$3K
- Steven StrykCanton$949K
- Hassan NasirWest Branch$736K
- Theodore KelbelGrand Rapids$695K
- Nicholas HartogGrand Rapids$575K
- Kathleen DassOak Park$446K
- Pulin PatelMount Clemens$431K
- Alan BaptistAnn Arbor$168K
- Mohsen NasirSaginaw$99K
- Abdul Husein BahrainwalaRoyal Oak$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.